Standard BioTools Inc. (LAB) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This Quarterly Report on Form 10-Q covers the period ended June 30, 2026. Standard BioTools Inc. is a life sciences company providing instrumentation, consumables, and services for proteomics and genomics. The reporting period is defined by two major strategic events: the completed sale of its SomaScan Business to Illumina (classified as discontinued operations) and the announcement of a proposed all-stock merger with Treeline Biosciences, Inc.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) |
|---|---|---|
| Total Revenue (Continuing Ops) | $20.1 million | $41.3 million |
| Gross Profit | $10.5 million | $21.8 million |
| Gross Margin | 52.4% | 53.0% |
| Net Loss from Continuing Operations | $(21.5) million | $(36.2) million |
| Net Income (Including Discontinued Ops) | $(26.8) million | $100.3 million |
| Cash and Cash Equivalents | $270.0 million (as of June 30, 2026) | |
| Total Investments | $274.0 million (Short-term + Long-term) | |
| Accumulated Deficit | $(1,160.2) million |
Material Changes vs. Prior Period
- Revenue: Total revenue from continuing operations decreased 8% year-over-year in Q2 2026 ($20.1M vs. $21.8M) and 2% year-over-year for the six months ended June 30, 2026 ($41.3M vs. $42.0M). The decline was driven by lower consumables and services revenue, partially offset by growth in the first quarter.
- Operating Expenses: Transaction and integration expenses surged to $14.7 million in Q2 2026 (up from $0.3 million in Q2 2025) due to the proposed merger with Treeline. Conversely, R&D and SG&A expenses decreased significantly (68% and 42% respectively in Q2) due to restructuring activities completed in 2025.
- Discontinued Operations: The six-month net income of $100.3 million is primarily driven by a $172.3 million pre-tax gain on the sale of the SomaScan Business to Illumina, which closed in January 2026. This contrasts with a net loss from discontinued operations in the prior year period.
- Liquidity: Cash and cash equivalents increased significantly to $270.0 million from $120.9 million at year-end 2025, bolstered by $388.2 million in proceeds from the SomaScan divestiture.
Guidance, Outlook, and Risks
- Merger with Treeline: On June 6, 2026, the Company entered into a merger agreement with Treeline Biosciences. The transaction is expected to close in the second half of 2026. Upon closing, Standard BioTools stockholders are expected to hold approximately 16% of the combined company, while Treeline stockholders will hold 84%. The Company will be renamed Treeline Biosciences Holdings, Inc.
- Contingent Value Rights (CVRs): Existing stockholders will receive CVRs entitling them to a pro-rata share of proceeds from the sale of the Company's remaining mass cytometry and microfluidics businesses ("Legacy Business") and other specified sources over a five-year term.
- Divestiture of Legacy Business: On July 28, 2026 (subsequent to period end), the Company entered into an agreement to sell its mass cytometry business to Multiplex Bio Inc. for up to $10.0 million.
- Nasdaq Listing Risk: The Company received notice on July 22, 2026, that it failed to meet the Nasdaq minimum bid price requirement ($1.00) again. It has until January 19, 2027, to regain compliance. Failure to do so could result in delisting.
- Restructuring: The Company continues to execute cost-reduction initiatives, including facility consolidations and workforce reductions, to align costs with revenue projections.
Investor Verification Checklist
- Verify the status of the Nasdaq compliance period regarding the minimum bid price requirement and any potential reverse stock split plans.
- Confirm the closing conditions for the Treeline merger, specifically stockholder approval and regulatory clearance.
- Review the terms of the Contingent Value Rights (CVRs) to understand the potential upside from the monetization of the Legacy Business.
- Monitor the sale of the mass cytometry business to Multiplex Bio Inc. and the expected timing of cash proceeds.
- Assess the impact of transaction and integration expenses on future cash burn rates post-merger.